Published in Bioorg Med Chem on June 02, 2005
Vesicular monoamine transporter 2: role as a novel target for drug development. AAPS J (2006) 1.78
A concise asymmetric synthesis of cis-2,6-disubstituted N-aryl piperazines via Pd-catalyzed carboamination reactions. Org Lett (2007) 1.19
Synthesis and evaluation of a series of homologues of lobelane at the vesicular monoamine transporter-2. Bioorg Med Chem Lett (2008) 1.11
Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. J Pharmacol Exp Ther (2011) 1.10
Synthesis and evaluation of a series of tropane analogues as novel vesicular monoamine transporter-2 ligands. Bioorg Med Chem Lett (2005) 1.06
Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry. Med Res Rev (2010) 0.99
Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse. Curr Top Med Chem (2011) 0.93
Phenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2. J Pharmacol Exp Ther (2010) 0.89
The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse. Adv Pharmacol (2014) 0.87
Computational neural network analysis of the affinity of lobeline and tetrabenazine analogs for the vesicular monoamine transporter-2. Bioorg Med Chem (2007) 0.82
Lobeline esters as novel ligands for neuronal nicotinic acetylcholine receptors and neurotransmitter transporters. Bioorg Med Chem (2009) 0.80
Exploring the effect of N-substitution in nor-lobelane on the interaction with VMAT2: discovery of a potential clinical candidate for treatment of methamphetamine abuse. Medchemcomm (2013) 0.79
1,4-Diphenalkylpiperidines: A new scaffold for the design of potent inhibitors of the vesicular monoamine transporter-2. Bioorg Med Chem Lett (2016) 0.78
Stereoselective Synthesis of Saturated Heterocycles via Pd-Catalyzed Alkene Carboetherification and Carboamination Reactions. Synlett (2006) 0.76
Synthesis of Lobeline, Lobelane and their Analogues. A Review. Org Prep Proced Int (2015) 0.75
Synthesis of symmetrical 1,5-disubstituted granatanines. Tetrahedron Lett (2008) 0.75
Lobelane analogues containing 4-hydroxy and 4-(2-fluoroethoxy) aromatic substituents: Potent and selective inhibitors of [(3)H]dopamine uptake at the vesicular monoamine transporter-2. Bioorg Med Chem Lett (2016) 0.75
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol (1973) 47.81
Brain reward circuitry: insights from unsensed incentives. Neuron (2002) 3.98
Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci (1995) 2.74
A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochem Pharmacol (2002) 2.51
Lobeline and nicotine evoke [3H]overflow from rat striatal slices preloaded with [3H]dopamine: differential inhibition of synaptosomal and vesicular [3H]dopamine uptake. J Pharmacol Exp Ther (1997) 2.14
Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. J Neuropsychiatry Clin Neurosci (2003) 2.14
Lobeline attenuates d-methamphetamine self-administration in rats. J Pharmacol Exp Ther (2001) 2.08
Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters. J Pharmacol Exp Ther (2004) 1.83
Lobeline inhibits the neurochemical and behavioral effects of amphetamine. J Pharmacol Exp Ther (2001) 1.77
Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine. J Neurochem (1998) 1.76
Lobeline does not serve as a reinforcer in rats. Psychopharmacology (Berl) (2002) 1.63
Lobeline: structure-affinity investigation of nicotinic acetylcholinergic receptor binding. J Med Chem (1999) 1.53
Lobeline inhibits nicotine-evoked [(3)H]dopamine overflow from rat striatal slices and nicotine-evoked (86)Rb(+) efflux from thalamic synaptosomes. Neuropharmacology (2000) 1.49
Inhibition of monoamine oxidase by amphetamine and related compounds. Biochem Pharmacol (1976) 1.49
Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter. Mol Pharmacol (1995) 1.34
Lobeline attenuates locomotor stimulation induced by repeated nicotine administration in rats. Pharmacol Biochem Behav (2003) 1.22
Lobeline and structurally simplified analogs exhibit differential agonist activity and sensitivity to antagonist blockade when compared to nicotine. Neuropharmacology (1998) 1.17
In vitro and in vivo studies of benzisoquinoline ligands for the brain synaptic vesicle monoamine transporter. J Med Chem (1996) 1.05
Amino- and amido-tetrabenazine derivatives: synthesis and evaluation as potential ligands for the vesicular monoamine transporter. Nucl Med Biol (1995) 0.98
Characterization of a series of 3-amino-2-phenylpropene derivatives as novel bovine chromaffin vesicular monoamine transporter inhibitors. J Med Chem (2003) 0.97
Indirect trapping of the retroconjugate addition reaction intermediate involved in the epimerization of lobeline: application to the synthesis of (-)-sedamine. J Org Chem (2004) 0.94
Rhodium-catalyzed addition of arylboronic acids to alkynyl aza-heteroaromatic compounds in water. J Org Chem (2003) 0.90
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Genetics of gene expression and its effect on disease. Nature (2008) 21.35
Mapping the genetic architecture of gene expression in human liver. PLoS Biol (2008) 19.44
Variations in DNA elucidate molecular networks that cause disease. Nature (2008) 12.04
An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet (2005) 11.40
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. Mol Cell (2007) 5.67
Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med (2009) 4.83
Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol (2008) 4.68
A generalized combinatorial approach for detecting gene-by-gene and gene-by-environment interactions with application to nicotine dependence. Am J Hum Genet (2007) 4.46
Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell (2013) 4.45
Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter. J Med Chem (2005) 3.32
Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A (2013) 3.25
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med (2015) 3.18
Novel substituted (Z)-2-(N-benzylindol-3-ylmethylene)quinuclidin-3-one and (Z)-(+/-)-2-(N-benzylindol-3-ylmethylene)quinuclidin-3-ol derivatives as potent thermal sensitizing agents. Bioorg Med Chem Lett (2007) 3.14
Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA (2007) 3.09
NADPH oxidase activity is essential for Keap1/Nrf2-mediated induction of GCLC in response to 2-indol-3-yl-methylenequinuclidin-3-ols. Cancer Res (2003) 3.02
A survey of the genetics of stomach, liver, and adipose gene expression from a morbidly obese cohort. Genome Res (2011) 3.00
Validation of candidate causal genes for obesity that affect shared metabolic pathways and networks. Nat Genet (2009) 2.97
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med (2008) 2.85
Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1). Bioorg Med Chem Lett (2009) 2.77
BioMagResBank database with sets of experimental NMR constraints corresponding to the structures of over 1400 biomolecules deposited in the Protein Data Bank. J Biomol NMR (2003) 2.74
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation (2013) 2.64
China's facility-based birth strategy and neonatal mortality: a population-based epidemiological study. Lancet (2011) 2.64
Integrating QTL and high-density SNP analyses in mice to identify Insig2 as a susceptibility gene for plasma cholesterol levels. Genomics (2005) 2.61
QTLNetwork: mapping and visualizing genetic architecture of complex traits in experimental populations. Bioinformatics (2008) 2.57
CsrA and three redundant small RNAs regulate quorum sensing in Vibrio cholerae. Mol Microbiol (2005) 2.56
Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke (2013) 2.52
A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochem Pharmacol (2002) 2.51
Association analyses identify six new psoriasis susceptibility loci in the Chinese population. Nat Genet (2010) 2.41
ToxR regulon of Vibrio cholerae and its expression in vibrios shed by cholera patients. Proc Natl Acad Sci U S A (2003) 2.29
Mapping the genetic architecture of complex traits in experimental populations. Bioinformatics (2007) 2.27
Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol (2005) 2.21
Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood (2010) 2.15
A paired-end sequencing strategy to map the complex landscape of transcription initiation. Nat Methods (2010) 2.14
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood (2007) 2.14
Detection of minor drug-resistant populations by parallel allele-specific sequencing. Nat Methods (2007) 2.09
Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res (2010) 2.06
Nuclear export and retention signals in the RS domain of SR proteins. Mol Cell Biol (2002) 2.04
Elucidating the murine brain transcriptional network in a segregating mouse population to identify core functional modules for obesity and diabetes. J Neurochem (2006) 2.00
Bidirectional control of social hierarchy by synaptic efficacy in medial prefrontal cortex. Science (2011) 1.97
Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood (2010) 1.92
Metabolism of bile salts in mice influences spore germination in Clostridium difficile. PLoS One (2010) 1.87
Disentangling molecular relationships with a causal inference test. BMC Genet (2009) 1.84
Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters. J Pharmacol Exp Ther (2004) 1.83
A new Vibrio cholerae sRNA modulates colonization and affects release of outer membrane vesicles. Mol Microbiol (2008) 1.83
Genetic and phenotypic diversity of quorum-sensing systems in clinical and environmental isolates of Vibrio cholerae. Infect Immun (2006) 1.82
Lobelane decreases methamphetamine self-administration in rats. Eur J Pharmacol (2007) 1.82
Vesicular monoamine transporter 2: role as a novel target for drug development. AAPS J (2006) 1.78
A Vibrio cholerae protease needed for killing of Caenorhabditis elegans has a role in protection from natural predator grazing. Proc Natl Acad Sci U S A (2006) 1.78
Multi-tissue coexpression networks reveal unexpected subnetworks associated with disease. Genome Biol (2009) 1.77
Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy. Mol Cancer Res (2011) 1.76
Forkhead transcription factor foxq1 promotes epithelial-mesenchymal transition and breast cancer metastasis. Cancer Res (2011) 1.71
Long-range polony haplotyping of individual human chromosome molecules. Nat Genet (2006) 1.69
Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. Nat Genet (2010) 1.69
PML nuclear bodies and apoptosis. Oncogene (2004) 1.66
A Bayesian partition method for detecting pleiotropic and epistatic eQTL modules. PLoS Comput Biol (2010) 1.66
Lobeline does not serve as a reinforcer in rats. Psychopharmacology (Berl) (2002) 1.63
Mucosal penetration primes Vibrio cholerae for host colonization by repressing quorum sensing. Proc Natl Acad Sci U S A (2008) 1.63
Transcription factor AtMYB103 is required for anther development by regulating tapetum development, callose dissolution and exine formation in Arabidopsis. Plant J (2007) 1.58
A combinatorial approach to detecting gene-gene and gene-environment interactions in family studies. Am J Hum Genet (2008) 1.57
Surface-plasmon-enhanced GaN-LED based on a multilayered M-shaped nano-grating. Opt Express (2013) 1.56
Bile acids stimulate biofilm formation in Vibrio cholerae. Mol Microbiol (2006) 1.56
A splicing-independent function of SF2/ASF in microRNA processing. Mol Cell (2010) 1.55
Association between green tea intake and coronary artery disease in a Chinese population. Circ J (2009) 1.54
RUPTURED POLLEN GRAIN1, a member of the MtN3/saliva gene family, is crucial for exine pattern formation and cell integrity of microspores in Arabidopsis. Plant Physiol (2008) 1.54
Characterization of endogenous human promyelocytic leukemia isoforms. Cancer Res (2006) 1.52
A constitutively active variant of the quorum-sensing regulator LuxO affects protease production and biofilm formation in Vibrio cholerae. Infect Immun (2003) 1.50
Cross-talk between JNK/SAPK and ERK/MAPK pathways: sustained activation of JNK blocks ERK activation by mitogenic factors. J Biol Chem (2003) 1.49
Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2. J Pharmacol Exp Ther (2009) 1.49
Genome-wide interaction-based association analysis identified multiple new susceptibility Loci for common diseases. PLoS Genet (2011) 1.46
Ultrastructural evidence of mitochondrial abnormalities in postresuscitation myocardial dysfunction. Resuscitation (2011) 1.46
N,N'-Alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: inhibition of nicotine-evoked dopamine release and hyperactivity. J Pharmacol Exp Ther (2008) 1.44
Prediabetes and short-term outcomes in nondiabetic patients after acute ST-elevation myocardial infarction. Cardiology (2013) 1.44
Rho and ROCK signaling in VEGF-induced microvascular endothelial hyperpermeability. Microcirculation (2006) 1.44
Highly efficient extraction of serum peptides by ordered mesoporous carbon. Angew Chem Int Ed Engl (2011) 1.43
Significance of 14-3-3 self-dimerization for phosphorylation-dependent target binding. Mol Biol Cell (2003) 1.42
Transcription initiation patterns indicate divergent strategies for gene regulation at the chromatin level. PLoS Genet (2011) 1.41
PfSETvs methylation of histone H3K36 represses virulence genes in Plasmodium falciparum. Nature (2013) 1.40
Melampomagnolide B: a new antileukemic sesquiterpene. Bioorg Med Chem (2011) 1.40
Subtype-selective nicotinic receptor antagonists: potential as tobacco use cessation agents. Bioorg Med Chem Lett (2004) 1.36
Prefrontal cortex and drug abuse vulnerability: translation to prevention and treatment interventions. Brain Res Rev (2010) 1.34
The HcrVf2 gene from a wild apple confers scab resistance to a transgenic cultivated variety. Proc Natl Acad Sci U S A (2004) 1.32
The effects of a novel nicotinic receptor antagonist N,N-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB) on acute and repeated nicotine-induced increases in extracellular dopamine in rat nucleus accumbens. Neuropharmacology (2006) 1.32